
Psilocybin Placebo Blinding: Why Trials Are Hard to Read
By Lily Pelenis / November 20, 2026 / 8 min read
Picture a psilocybin trial. Within about an hour, nearly everyone in the room knows who got the real dose. That is the whole psilocybin placebo blinding problem in one scene: the effects are so obvious that people can usually tell whether they got the drug, and that knowledge can colour the results. Researchers fight back with active placebos such as niacin or a tiny dose of psilocybin, but no design fully solves it yet.
TLDR
A blinded trial hides who gets the drug and who gets the placebo, so hope and disappointment cannot tip the results. With psilocybin, the trip gives the game away. A 2026 review by a Toronto team found that psilocybin, LSD and ayahuasca trials often reported that more than 90% of participants and raters guessed correctly.
That does not mean psilocybin is “just placebo.” It means the size of the effect is hard to pin down. When one 2024 analysis compared psilocybin with the placebo response seen in antidepressant trials, its advantage shrank from large to small but did not vanish.
For microdosing, the best placebo-controlled study so far, with 191 people, found no difference between microdoses and empty capsules over four weeks.
Quick facts
- Over 90%
- guessed right in many psilocybin trials
- 33 of 112
- psychedelic trials checked their blinding
- 0.88 to 0.31
- psilocybin effect size with a fairer baseline
- 191 people
- in a microdose study that matched placebo
Who this article is for
- You saw a headline saying psilocybin beat an antidepressant and want to know how much to trust it.
- Someone told you mushrooms only work because people expect them to.
- You microdose and wonder how much of what you feel is the mushroom.
- You like science but get lost in words like “double-blind” and “active comparator.”
Lily Pelenis
Author’s note
This piece began as a letter to our newsletter readers in September 2024, about what the placebo effect really is. I came back to it in October 2026, when a new trial design caught my eye. The design was more interesting than the headline, and it explained a lot about how this research works.
I am a Toronto-based lifestyle coach and yoga instructor, and I have worked with psilocybin for over a decade. I care about intention and integration, and part of that is being clear about what the science shows and what it does not. Once you understand blinding, I think you become much harder to mislead by a headline, in either direction.
What does blinding mean in a psilocybin trial?
Blinding means the people in a trial do not know who got the real treatment. In a “double-blind” trial, neither the participants nor the staff know. The goal is to make sure any difference between groups comes from the drug, not from hope or expectation.
The placebo effect is not “nothing”
Expectation is powerful. In a study of 66 people with migraine, a placebo accounted for more than half of the drug’s effect on pain. The more positive the label on the pill, the better both the placebo and the real drug worked. Even a pill openly labelled “placebo” beat no treatment at all. I keep that study in mind whenever someone says a placebo is “just in your head.”
Why a sugar pill fails here
A sugar pill works as a blind for many medicines because they feel like nothing at first. Psilocybin is different. If you see colours breathing on the wall, you know. People in the placebo group know too, and they may feel let down. Researchers call this “functional unblinding.”
A 2021 review by Muthukumaraswamy, Forsyth and Lumley argued that effect sizes in psychedelic trials are likely overestimated for this reason. They found most trials had not measured expectations before the study or whether the blind held.
How often does functional unblinding happen?
Very often. A 2026 systematic review by Orsini and colleagues, a team from the University of Toronto and Toronto hospitals, looked at 112 psychedelic trials for mental health. Only 33 of them, 29.5%, checked whether the blind held, even though 64 named blinding as a limitation.
I find that gap striking. Where it was measured, the blind often failed. Psilocybin, LSD and ayahuasca studies frequently reported that more than 90% of participants and raters guessed right. No control strategy kept the blind reliably.
Only 33 of 112 psychedelic trials in a 2026 review checked whether their blinding actually held.
Raters can be unblinded too
It is not only the participants. This is the part I wish more coverage explained. The person scoring the depression scale may notice who had a big day. An assessor who knows the answer tends, without meaning to, to find it. That is why better trials keep the raters separate from the dosing session.
Even an active placebo leaks
In a 2026 Swiss trial of 120 healthy volunteers, Belinger and colleagues gave psilocybin, MDMA or methylphenidate, a stimulant used as an active placebo. Blinding was insufficient overall, and psilocybin had the highest rate of unblinding of the three.
What do researchers use as an active placebo?
An active placebo is a control that causes some noticeable effect, so people cannot easily tell they missed out. Psilocybin trials have used niacin, which causes flushing, the stimulant methylphenidate, and very low doses of psilocybin itself.
| Control used | Trial and size | What the control does |
|---|---|---|
| Methylphenidate | Griffiths et al., 2006: 36 healthy volunteers | A stimulant that makes you feel something |
| Niacin | Ross et al., 2016: 29 people with cancer | A vitamin that causes warmth and flushing |
| Niacin, 100 mg | Raison et al., 2023: 104 people with depression | Same idea, in identical capsules |
| Psilocybin, 1 mg | Goodwin et al., 2022: 233 people | A dose too small to cause a trip |
| Psilocybin, 5 mg | UCSF PRISM trial: 30 planned | A real but much smaller dose |
Comparing doses instead of drug vs nothing
A low dose turns the question into “how much does the dose matter?” In the Goodwin trial, 233 people with hard-to-treat depression got 25 mg, 10 mg or 1 mg. After three weeks, 25 mg beat 1 mg, but 10 mg did not. One of the coauthors works at CAMH in Toronto.
The new PRISM trial at UCSF uses the same logic. Thirty people living with HIV and methamphetamine use disorder will get 25 mg or 5 mg. Participants, care providers, investigators and outcome assessors are all masked. Its main measures are recruitment, completion, retention, acceptability and side effects, not whether it works. A study this size earns the right to run a bigger one.
Ideas still being tested
A 2025 paper by Aday and colleagues lists what a good active placebo needs. It should cause effects you can feel in mind and body. It should start and last about as long as the real drug. It must be safe, and it must not treat the condition itself. Muthukumaraswamy (2023) suggests tracking measurable body or brain markers to test whether the drug works through a real pathway.
Is psilocybin just a placebo effect?
No, the evidence does not say that, but it does say the benefit is probably smaller than early numbers suggested. Three recent analyses look at the problem from different angles.
A fairer baseline shrinks the effect
A 2024 BMJ network meta-analysis from Taiwan by Hsu and colleagues noticed that placebo groups in psychedelic trials improve less than placebo groups in antidepressant trials. Using the antidepressant trials’ placebo as the baseline, high-dose psilocybin’s effect size fell from large (0.88) to small (0.31). It was still the only psychedelic that beat that baseline.
A 2025 analysis by Hieronymus and colleagues found the same pattern across 17 trials. Response rates for the control groups were 14 percentage points higher in SSRI trials than in psilocybin trials.
Open label against open label
A 2026 meta-analysis by Williams, Barnett and Szigeti took a different route. Psychedelic therapy is open label in practice, since people can tell. So they compared it with antidepressant trials where patients knew what they took. Across 8 psychedelic trials with 249 patients, psychedelic therapy did no better.
Expectation may not explain it all, though. Take the 59-person Imperial College trial. Szigeti and colleagues (2024) found patients hoped for more from psilocybin. Yet hope predicted who got better on the antidepressant, not on psilocybin. With 55 people analysed, I treat it as a finding worth watching, not a verdict.
Lily’s take
I do not find any of this deflating. A smaller, honest number is something I can actually plan around, and I would rather hear the dull answer than a shiny one that falls apart.
What about microdosing?
Microdosing is where the placebo question bites hardest. In a 2021 “self-blinding” study by Szigeti and colleagues, 191 people mixed real microdoses and empty capsules at home without knowing which was which. Both groups improved over four weeks, with no significant difference. Small dose-day differences could be explained by people breaking the blind.
In a self-blinded study of 191 microdosers, people taking empty capsules improved as much as people taking real microdoses.
A 2023 lab-plus-home trial of 80 healthy men by Murphy and colleagues, using LSD microdoses, found brighter mood on dose days but no lasting change after six weeks. If you microdose, I would still keep a simple log of dose and non-dose days. A Golden Teacher Microdosing Capsule holds 125 mg, and Golden Teacher Gummies for Microdosing hold 100 mg each, so the amount stays the same from day to day. My piece on how long microdosing takes to work covers what to track.
How should you read the next psilocybin study?
I look at the design before the headline: who the control group was, whether blinding was checked, how many people took part and what phase the trial was in. Most of the answers are in the abstract or the trial’s registry entry.
Try this
- Find the comparisonCheck whether psilocybin was compared with nothing, niacin, a low dose or another medicine.
- Look for a blinding checkSee whether the authors asked people to guess their group.
- Count the peopleTreat a trial of 30 as a first look, not a final answer.
- Check the phasePhase 1 and 2 trials test safety and dose; phase 3 tests whether it works at scale.
- Read the registrySearch the trial number on ClinicalTrials.gov to see the planned main outcome.
Where things stand in Canada
Health Canada says there are no approved therapeutic products containing psilocybin in Canada or elsewhere, and that clinical trials are the best way to advance the research. Doctors can also request psilocybin through the Special Access Program, which was restored in January 2022 for restricted drugs. That is part of why I care about better blinding: approval in Canada depends on trials that hold up.
For a wider checklist, read these five questions before you believe a mushroom claim and whether microdosing helps people work better. My piece on whether psilocybin can change your personality shows the same limits in another area. If you trip, our dosing guide explains the six dose levels, and the same caution applies from Winnipeg to the coast: start low.
FAQ
What does unblinding mean in clinical trials?
Unblinding is when people in a trial learn which group someone is in. It can happen by design at the end, or by accident. In psychedelic trials it often happens through the drug itself, which is called functional unblinding: people can feel whether they got the real dose. A 2026 review found many psilocybin trials reported that more than 90% guessed right.
Does blinding reduce placebo effects?
No. Blinding does not remove the placebo effect; it spreads it across both groups, so the difference left over reflects the drug. In a 2026 meta-analysis, blinding changed results for antidepressant trials but not for psychedelic therapy, which suggests psychedelic trials are in practice open label.
Is microdosing a placebo?
The best evidence so far suggests much of the reported benefit may be. In a self-blinded study of 191 people, those taking empty capsules improved as much as those taking microdoses over four weeks. That does not rule out effects for every person, and larger trials are still needed.
Does psilocybin permanently change your brain?
That has not been shown. In a 2017 study of 19 people with depression, Carhart-Harris and colleagues saw changes in brain blood flow and connectivity after treatment. The study had no control group and did not test how long the changes lasted.
Find your strain, then your dose
Every product on the shelf shows its potency rating and the effects people report. The dosing guide walks through amounts before you order, and a real person answers if you write to us.
About the author
Lily Pelenis
I'm a Toronto-based lifestyle coach, psilocybin enthusiast and certified yoga instructor. I guide people toward mindful, balanced living, and my coaching blends modern wellness practices with ancient wisdom to help clients find deeper self-awareness, resilience and joy.
I've been experimenting with shrooms for over a decade, and I write about my own experience. I love nature, psychology and humans. That is why my articles tend to follow a trip past its peak and into the weeks after it.
Some pieces start with a strain I have tried myself, such as Golden Teacher or Albino Roller Coaster. Others are the practical ones, like how much to take the first time or how to brew a tea that sits easier on the stomach. Over the years I've learned that intention is everything, so I write about why you are taking it before I get to how.
50% off your first order
New strains, restocks, sales and new writing from the Notebook, by email. No spam, unsubscribe any time.









